Modification of MDMX by sumoylation

Biochemical and Biophysical Research Communications

Volumn 332, Issue 3, 2005, Pages 702-709

  Pan, Yu ^a   Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

ARF; Degradation; MDM2; MDMX; p53; Sumoylation; Ubiquitination

Indexed keywords

LYSINE; PROTEIN MDM2; PROTEIN P53; SUMO 1 PROTEIN;

ARTICLE; CONJUGATION; CONTROLLED STUDY; DNA DAMAGE; EXPERIMENTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN MODIFICATION; SEQUENCE HOMOLOGY; UBIQUITINATION; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT PROTEINS; SEQUENCE DELETION; SUMO-1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 19744363342     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.05.012     Document Type: Article

References (35)

1. Y. Zhang, and Y. Xiong Control of p53 ubiquitination and nuclear export by MDM2 and ARF Cell Growth Differ. 12 2001 175 186
2. C. Prives, and P.A. Hall The p53 pathway J. Pathol. 187 1999 112 126
3. C.J. Sherr Tumor surveillance via the ARF-p53 pathway Genes Dev. 12 1998 2984 2991
4. E. Kobet, X. Zeng, Y. Zhu, D. Keller, and H. Lu MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins Proc. Natl. Acad. Sci. USA 97 2002 12547 12552
5. A. Ito, C.H. Lai, X. Zhao, S. Saito, M.H. Hamilton, E. Appella, and T.P. Yao p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2 EMBO J. 20 2001 1331 1340
6. A. Ito, Y. Kawaguchi, C.H. Lai, J.J. Kovacs, Y. Higashimoto, E. Appella, and T.P. Yao MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation EMBO J. 21 2002 6236 6245
7. A. Shvarts, W.T. Steegenga, N. Riteco, T. van Larr, P. Dekker, M. Bazuine, R.C.A. van Ham, W.V.D.H. van Oordt, G. Hateboer, A.J. van der Eb, and A.G. Jochemsen MDMX: a novel p53-binding protein with some functional properties of MDM2 EMBO J. 15 1996 5349 5357
8. R. Stad, N.A. Little, D.P. Xirodimas, R. Frenk, A.J. van der Eb, D.P. Lane, M.K. Saville, and A.G. Jochemsen Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms EMBO Rep. 2 2001 1029 1034
9. J.C. Badciong, and A.L. Haas MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination J. Biol. Chem. 277 2002 49668 49675
10. L.K. Linares, A. Hengstermann, A. Ciechanover, S. Muller, and M. Scheffner HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 Proc. Natl. Acad. Sci. USA 100 2003 12009 12014
11. R.M. Oca Luna, D.S. Wagner, and G. Lozano Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 378 1995 203 206
12. J. Parant, A. Chavez-Reyes, N.A. Little, W. Yan, V. Reinke, A.G. Jochemsen, and G. Lozano Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 Nat. Genet. 29 2002 92 95
13. R.A. Finch, D.B. Donoviel, D. Potter, M. Shi, A. Fan, D.D. Freed, C.Y. Wang, B.P. Zambrowicz, R. Ramirez-Solis, A.T. Sands, and N. Zhang mdmx is a negative regulator of p53 activity in vivo Cancer Res. 62 2002 3221 3225
14. D. Migliorini, E.L. Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P.G. Pelicci, and J.C. Marine Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development Mol. Cell. Biol. 22 2002 5527 5538
15. Y.F. Ramos, R. Stad, J. Attema, L.T. Peltenburg, A.J. van der Eb, and A.G. Jochemsen Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53 Cancer Res. 61 2002 1839 1842
16. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. De Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, and J.C. Marine Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity Mol. Cell. Biol. 24 2004 5835 5843
17. M. Gostissa, A. Hengstermann, V. Fogal, P. Sandy, S.E. Schwarz, M. Scheffner, and G. Del Sal Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1 EMBO J. 18 1999 6462 6471
18. M.S. Rodriguez, J.M. Desterro, S. Lain, C.A. Midgley, D.P. Lane, and R.T. Hay SUMO-1 modification activates the transcriptional response of p53 EMBO J. 18 1999 6455 6461
19. S. Muller, M. Berger, F. Lehembre, J.S. Seeler, Y. Haupt, and A. Dejean c-Jun and p53 activity is modulated by SUMO-1 modification J. Biol. Chem. 275 2002 13321 13329
20. D.P. Xirodimas, J. Chisholm, J.M. Desterro, D.P. Lane, and R.T. Hay P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2 FEBS Lett. 528 2002 207 211
21. M. Hochstrasser SP-RING for SUMO: new functions bloom for a ubiquitin-like protein Cell 107 2002 5 8
22. M.S. Rodriguez, C. Dargemont, and R.T. Hay SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting J. Biol. Chem. 276 2002 12654 12669
23. L. Chen, and J. Chen MDM2-ARF complex regulates p53 sumoylation Oncogene 22 2003 5348 5357
24. S.S. Kwek, J. Derry, A.L. Tyner, Z. Shen, and A.V. Gudkov Functional analysis and intracellular localization of p53 modified by SUMO-1 Oncogene 20 2002 2587 2599
25. A. Minty, X. Dumont, M. Kaghad, and D. Caput Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif J. Biol. Chem. 275 2002 36316 36323
26. Y. Pan, and J. Chen MDM2 promotes ubiquitination and degradation of MDMX Mol. Cell. Biol. 23 2003 5113 5121
27. H. Kawai, D. Wiederschain, H. Kitao, J. Stuart, K.K. Tsai, and Z.M. Yuan DNA damage-induced MDMX degradation is mediated by MDM2 J. Biol. Chem. 278 2003 45946 45953
28. P. De Graaf, N.A. Little, Y.F. Ramos, E. Meulmeester, S.J. Letteboer, and A.G. Jochemsen Hdmx protein stability is regulated by the ubiquitin ligase activity of mdm2 J. Biol. Chem. 278 2003 38315 38324
29. D. Xirodimas, M.K. Saville, C. Edling, D.P. Lane, and S. Lain Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo Oncogene 20 2002 4972 4983
30. Y. Zhang, and Y. Xiong Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 Mol. Cell 3 1999 579 591
31. L. Gong, S. Millas, G.G. Maul, and E.T. Yeh Differential regulation of sentrinized proteins by a novel sentrin-specific protease J. Biol. Chem. 275 2002 3355 3359
32. J. Chen, V. Marechal, and A.J. Levine Mapping of the p53 and mdm-2 interaction domains Mol. Cell. Biol. 13 1993 4107 4114
33. J. Chen, J. Lin, and A.J. Levine Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene Mol. Med. 1 1995 142 152
34. Changgong Li, Lihong Chen, and Jiandong Chen DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms Mol. Cell. Biol. 22 2002 7562 7571
35. F. Melchior, and L. Hengst SUMO-1 and p53 Cell Cycle 1 2002 245 249